Evidence map›Paper›PMID 40137199›Full record

ReviewJournal of imaging2025

Advances in Optical Contrast Agents for Medical Imaging: Fluorescent Probes and Molecular Imaging.

Divya Tripathi, Mayurakshi Hardaniya, Suchita Pande, Dipak Maity

Abstract readReview
In one paragraph

Review in Journal of imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Stimuli-Responsive Materials for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Divya TripathiSchool of Health Sciences, University of Petroleum and Energy Studies, Dehradun 248007, India.
Mayurakshi HardaniyaSchool of Health Sciences, University of Petroleum and Energy Studies, Dehradun 248007, India.
Suchita PandeSchool of Health Sciences, University of Petroleum and Energy Studies, Dehradun 248007, India.
Dipak MaityIntegrated Nanosystems Development Institute, Indiana University, Indianapolis, IN 46202, USA.ORCID 0000-0001-9792-0281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optical imaging is an excellent non-invasive method for viewing visceral organs. Most importantly, it is safer as compared to ionizing radiation-based methods like X-rays. By making use of the properties of photons, this technique generates high-resolution images of cells, molecules, organs, and tissues using visible, ultraviolet, and infrared light. Moreover, optical imaging enables real-time evaluation of soft tissue properties, metabolic alterations, and early disease markers in real time by utilizing a variety of techniques, including fluorescence and bioluminescence. Innovative biocompatible fluorescent probes that may provide disease-specific optical signals are being used to improve diagnostic capabilities in a variety of clinical applications. However, despite these promising advancements, several challenges remain unresolved. The primary obstacle includes the difficulty of developing efficient fluorescent probes, and the tissue autofluorescence, which complicates signal detection. Furthermore, the depth penetration restrictions of several imaging modalities limit their use in imaging of deeper tissues. Additionally, enhancing biocompatibility, boosting fluorescent probe signal-to-noise ratios, and utilizing cutting-edge imaging technologies like machine learning for better image processing should be the main goals of future research. Overcoming these challenges and establishing optical imaging as a fundamental component of modern medical diagnoses and therapeutic treatments would require cooperation between scientists, physicians, and regulatory bodies.

Indexed as

contrast agentsfluorescent probemedical imagingmolecular imagingoptical imagingtherapeutics

Identifiers

PMID40137199
PMCPMC11942650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.